HOTH•benzinga•
Hoth Therapeutics Announces Key Opinion Leader Event Showcasing HT-001, Topical Therapeutic, Designed To Treat Debilitating Skin Toxicities Caused By EGFR Inhibitor Cancer Therapies
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 5, 2025 by benzinga